After scrabbling for early financing, Engage Therapeutics has some positive clinical data to show the world.
It’s a particularly poignant win for Engage, which was founded by the father of a child with uncontrolled epilepsy in hopes that the company’s treatments will help tame his and other children’s seizures. The company reported new data Thursday that shows that among the 76 people who took the company’s drug — an inhalable form of the drug commonly known as Xanax — nearly two-thirds were able to halt a seizure immediately before or after it began.
About the Author Reprints
